Cytomegalovirus retinitis

International Ophthalmology Clinics

Volumn 46, Issue 2, 2006, Pages 91-110

  Wiegand, Torsten W ^a   Young, Lucy H Y ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMO 5,6 DICHLORO 1 BETA DEXTRO RIBORFURANOSYLBENZIMIDAZOLE RIBOSIDE; 2,5,6 TRICHLORO 1 BETA DEXTRO RIBORFURANOSYLBENZIMIDAZOLE RIBOSIDE; ACICLOVIR; ACTG 266; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; DOUBLE STRANDED DNA; EOSIN; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GW 275175 X; HEMATOXYLIN; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PROBENECID; TOMEGLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CILIARY DISK; CLINICAL TRIAL; CONFERENCE PAPER; CONGENITAL INFECTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; EPSTEIN BARR VIRUS; FEVER; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; LENS IMPLANTATION; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; ORGAN TRANSPLANTATION; PERINATAL INFECTION; PLACENTAL TRANSFER; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RETINA DEGENERATION; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; RETINA PIGMENT EPITHELIOPATHY; RETINA SURGERY; RETINITIS; SCREENING; SLIT LAMP; TOXOPLASMA GONDII; TREPONEMA PALLIDUM; UNSPECIFIED SIDE EFFECT; UVEITIS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS TRANSMISSION; VISUAL FIELD DEFECT; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

EID: 33746149216     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200604620-00010     Document Type: Conference Paper

References (134)

1. Marshall GS, Rabalais GP, Stewart JA, et al. Cytomegalovirus seroprevalence in women bearing children in Jefferson County, Kentucky. Am J Med Sci. 1993;305:292-296.
2. Pass RF. Epidemiology and transmission of cytomegalovirus. J Infect Dis. 1985;152:243-248.
3. Sohn YM, Oh MK, Balcarek KB, et al. Cytomegalovirus infection in sexually active adolescents. J Infect Dis. 1991;163:460-463.
4. Crippa F, Corey L, Chuang EL, et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214-219.
5. Ciardella AP, Barile G, Langton K, et al. Cytomegalovirus retinitis and FK 506. Am J Ophthalmol. 2003;136:386-389.
6. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223-1227.
7. Montaner JS, Le T, Hogg R, et al. The changing spectrum of AIDS index diseases in Canada. AIDS. 1994;8:693-696.
8. Munoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol. 1993;137:423-438.
9. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069-1074.
10. Holland G, Tufail A, Jordan MC. Cytomegalovirus diseases. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection & Immunity. New York: Mosby; 1996.
11. Harooni M, Lashkari K, Freilich JM, et al. Cytomegalovirus retinitis. Int Ophthalmol Clin. 1996;36:131-140.
12. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol. 1997;124:227-233.
13. Jacobson MA, Stanley H, Holtzer C, et al. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:231-233.
14. Mahadevia PJ, Gebo KA, Pettit K, et al. The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-HAART era among a national managed-care population. J Acquir Immune Defic Syndr. 2004;36:972-977.
15. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282:1633-1637.
16. Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48-61.
17. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111:2224-2231.
18. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111:2232-2239.
19. Lewis JS II, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther. 1997;19:187-214.
20. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-29.
21. Dunn W, Chou C, Li H, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A. 2003;100:14223-14228.
22. Fields BN, Knipe DM, Howley PM, et al. Fields' virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001;2:72;xix, 3087.
23. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-738.
24. Gerna G, Baldanti F, Revello MG. Pathogenesis of human cytomegalovirus infection and cellular targets. Hum Immunol. 2004;65:381-386.
25. Bodaghi B, Slobbe-van Drunen ME, Topilko A, et al. Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis. Invest Ophthalmol Vis Sci. 1999;40:2598-2607.
26. Halary F, Amara A, Lortat-Jacob H, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity. 2002;17:653-664.
27. Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40:3177-3185.
28. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc. 1998;96:111-123; discussion 24-26.
29. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol Rev. 1997;159:31-48.
30. Chiou SH, Liu JH, Chen SS, et al. Apoptosis of human retina and retinal pigment cells induced by human cytomegalovirus infection. Ophthalmic Res. 2002;34:77-82.
31. Scholz M, Doerr HW, Cinatl J. Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol. 2003;11:171-178.
32. Dix RD, Ekworomadu CO, Hernandez E, et al. Perform knockout mice, but not mice with MAIDS, show protection against experimental cytomegalovirus retinitis after adoptive transfer of immune cells with a functional perform cytotoxic pathway. Arch Virol. 2004;149:2235-2244.
33. Kashiwase M, Yamauchi Y, Sata T, et al. Histopathological findings in cytomegalovirus retinitis. Nippon Ganka Gakkai Zasshi. 2004;108:415-422.
34. Mattes FM, McLaughlin JE, Emery VC, et al. Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7. J Clin Pathol. 2000;53:612-614.
35. Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Arch Ophthalmol. 1992;110:1435-1442.
36. Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J Infect. 2002;44:78-83.
37. Cacopardo B, Nigro L. Clinical features of cytomegalic disease in immunocompetent subjects: a 1990-2000 survey. Ann Ital Med Int. 2003;18:83-88.
38. Kyto V, Vuorinen T, Saukko P, et al. Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Clin Infect Dis. 2005;40:683-688.
39. Karakelides H, Aubry MC, Ryu JH. Cytomegalovirus pneumonia mimicking lung cancer in an immunocompetent host. Mayo Clin Proc. 2003;78:488-490.
40. Stratton KRKJ, Lawrence RS. Vaccines for the 21st Century: A Tool for Decision Making. Washington: National Academy Press; 2000.
41. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256:1904-1908.
42. Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics. 1999;104:55-60.
43. Trincado DE, Rawlinson WD. Congenital and perinatal infections with cytomegalovirus. J Paediatr Child Health. 2001;37:187-192.
44. Stephan F, Meharzi D, Ricci S, et al. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation. Intensive Care Med. 1996;22:1244-1249.
45. Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis. 1997;176:1484-1490.
46. Tolkoff-Rubin NE, Rubin RH. The interaction of immunosuppression with infection in the organ transplant recipient. Transplant Proc. 1994;26:16-19.
47. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001;12:848-855.
48. Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant. 1998;21(Suppl 2):S72-S74.
49. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood. 2000;95:2240-2245.
50. Gandhi MK, Wills MR, Sissons JG, et al. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev. 2003;17:259-264.
51. Wei LL, Park SS, Skiest DJ. Prevalence of visual symptoms among patients with newly diagnosed cytomegalovirus retinitis. Retina. 2002;22:278-282.
52. Hodge WG, Boivin JF, Shapiro SH, et al. Clinical risk factors for cytomegalovirus retinitis in patients with AIDS. Ophthalmology. 2004;111:1326-1333.
53. Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466-476.
54. Walker S, Iguchi A, Jones NP. Frosted branch angiitis: a review. Eye. 2004;18:527-533.
55. Mansour AM. Cytomegalovirus optic neuritis. Curr Opin Ophthalmol. 1997;8:55-58.
56. Patel SS, Rutzen AR, Marx JL, et al. Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Ophthalmology. 1996;103:1476-1482.
57. Holland GN, Buhles WC Jr, Mastre B, et al. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy Study Group. Arch Ophthalmol. 1989;107:1759-1766.
58. Cunningham ET, Pepose JS, Holland GN. Cytomegalovirus Infections of the Retina. In: Ryan SJ, ed. Retina. London: Mosby; 2001.
59. Glasgow BJ, Weisberger AK. A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency syndrome. Am J Ophthalmol. 1994;118:46-56.
60. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1990;97:681-686.
61. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
62. Sarrafizadeh R, Weinberg DV, Huang CF. An analysis of lesion size and location in newly diagnosed cytomegalovirus retinitis. Ophthalmology. 2002;109:119-125.
63. Wren SM, Fielder AR, Bethell D, et al. Cytomegalovirus retinitis in infancy. Eye. 2004;18:389-392.
64. Kuo IC, Kempen JH, Dunn JP, et al. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol. 2004;138:338-346.
65. AIDS Clinical Trials Group (ACTG). Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials. 1992;13:22-39.
66. Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). Am J Ophthalmol. 1997;124:61-70.
67. Kempen JH, Jabs DA, Dunn JP, et al. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol. 2001;119:33-40.
68. Jabs DA, Enger C, Haller J, et al. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol. 1991;109:794-799.
69. Althaus C, Loeffler KU, Schimkat M, et al. Prophylactic argon laser coagulation for rhegmatogenous retinal detachment in AIDS patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1998;236:359-364.
70. Young S, McCluskey P, Minassian DC, et al. Retinal detachment in cytomegalovirus retinitis: intravenous versus intravitreal therapy. Clin Experiment Ophthalmol. 2003;31:96-102.
71. Freidlin J, Sharma MC, Goldstein DA. Subretinal hemorrhage in cytomegalovirus retinitis. Ophthalmic Surg Lasers Imaging. 2005;36:73-75.
72. Sanislo SR, Lowder CY, Kaiser PK. Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery. Am J Ophthalmol. 1998;126:318-320.
73. Bogie GJ, Nanda SK. Neovascularization associated with cytomegalovirus retinitis. Retina. 2001;21:85-87.
74. Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol. 2004;49:131-157.
75. Tran TH, Stanescu D, Caspers-Velu L, et al. Clinical characteristics of acute HSV-2 retinal necrosis. Am J Ophthalmol. 2004;137:872-879.
76. Cunningham ET Jr, Short GA, Irvine AR, et al. Acquired immunodeficiency syndrome-associated herpes simplex virus retinitis. Clinical description and use of a polymerase chain reaction-based assay as a diagnostic tool. Arch Ophthalmol. 1996;114:834-840.
77. Akpek EK, Kent C, Jakobiec F, et al. Bilateral acute retinal necrosis caused by cytomegalovirus in an immunocompromised patient. Am J Ophthalmol. 1999;127:93-95.
78. Biswas J, Choudhry S, Priya K, et al. Detection of cytomegalovirus from vitreous humor in a patient with progressive outer retinal necrosis. Indian J Ophthalmol. 2002;50:319-321.
79. Durnian JM, Naylor G, Saeed AM. Ocular syphilis: the return of an old acquaintance. Eye. 2004;18:440-442.
80. McLeish WM, Pulido JS, Holland S, et al. The ocular manifestations of syphilis in the human immunodeficiency virus type 1-infected host. Ophthalmology. 1990;97:196-203.
81. Aldave AJ, King JA, Cunningham ET Jr. Ocular syphilis. Curr Opin Ophthalmol. 2001;12:433-441.
82. Shalaby IA, Dunn JP, Semba RD, et al. Syphilitic uveitis in human immunodeficiency virus-infected patients. Arch Ophthalmol. 1997;115:469-473.
83. Haas JS, Bolan G, Larsen SA, et al. Sensitivity of treponemal tests for detecting prior treated syphilis during human immunodeficiency virus infection. J Infect Dis. 1990;162:862-866.
84. Levy JH, Liss RA, Maguire AM. Neurosyphilis and ocular syphilis in patients with concurrent human immunodeficiency virus infection. Retina. 1989;9:175-180.
85. Holland GN, Engstrom RE Jr, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653-667.
86. Dunn JP, Jabs DA. Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. AIDS Clin Rev. 1995:99-129.
87. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange. Timing, surgical procedure, and complications. Arch Ophthalmol. 1997;115:1389-1394.
88. Hatton MP, Duker JS, Reichel E, et al. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina. 1998;18:50-55.
89. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1999;127:288-293.
90. Dunn JP, Van Natta M, Foster G, et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina. 2004;24:41-50.
91. Lalezari JP, Friedberg DN, Bissett J, et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol. 2002;24:67-77.
92. Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135:26-34.
93. Imai Y, Shum C, Martin DF, et al. Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir. J Infect Dis. 2004;189:611-615.
94. Segarra-Newnham M, Salazar MI. Valganciclovir: a new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals. Pharmacotherapy. 2002;22:1124-1128.
95. Lalezari J, Lindley J, Walmsley S, et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr. 2002;30:392-400.
96. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119-1126.
97. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment. Prescrire Int. 2003;12:133-135.
98. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-1261.
99. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med. 1992:326:213-220.
100. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med. 1995;155:65-74.
101. Ohta H, Matsuda Y, Tokimasa S, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Bone Marrow Transplant. 2001;27:1141-1145.
102. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. 1996;62:376-380.
103. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995;171:788-796.
104. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. AIDS. 2000;14:1571-1581.
105. Jacobson MA, Wilson S, Stanley H, et al. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin Infect Dis. 1999;28:528-533.
106. Akler ME, Johnson DW, Burman WJ, et al. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105:651-657.
107. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol. 1997;115:733-737.
108. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1995;102:533-542; discussion 42-43.
109. Kersten A, Althaus C, Hudde T, et al. Intravitreal injection of cidofovir in cytomegalovirus retinitis. Ophthalmologe. 1998;95:602-606.
110. Randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:467-474.
111. Detrick B, Nagineni CN, Grillone LR, et al. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. Invest Ophthalmol Vis Sci. 2001;42:163-169.
112. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol. 2002;133:475-483.
113. Stone TW, Jaffe GJ. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. Am J Ophthalmol. 2000;130:242-243.
114. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:484-498.
115. Jabs DA, Griffiths PD. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol. 2002;133:552-556.
116. Borucki MJ, Spritzler J, Asmuth DM, et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res. 2004;64:103-111.
117. Nixon DE, McVoy MA. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D- ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J Virol. 2004;78:1623-1635.
118. Underwood MR, Ferris RG, Selleseth DW, et al. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother. 2004;48:1647-1651.
119. Schleiss MR, Bernstein DI, McVoy MA, et al. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 2005;65:35-43.
120. Evers DL, Komazin G, Ptak RG, et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother. 2004;48:3918-3927.
121. Dix RD, Cousins SW. Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis. Curr HIV Res. 2004;2:333-342.
122. Dix RD, Cousins SW. Susceptibility to murine cytomegalovirus retinitis during progression of MAIDS: correlation with intraocular levels of tumor necrosis factor-alpha and interferon-gamma. Curr Eye Res. 2004;29:173-180.
123. Davis JL. Management of CMV retinal detachments in the new era of antiretroviral therapy. Ocul Immunol Inflamm. 1999;7:205-213.
124. Irvine AR, Lonn L, Schwartz D, et al. Retinal detachment in AIDS: long-term results after repair with silicone oil. Br J Ophthalmol. 1997;81:180-183.
125. Davis JL, Serfass MS, Lai MY, et al. Silicone oil in repair of retinal detachments caused by necrotizing retinitis in HIV infection. Arch Ophthalmol. 1995;113:1401-1409.
126. Tanna AP, Kempen JH, Dunn JP, et al. Incidence and management of cataract after retinal detachment repair with silicone oil in immune compromised patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;136:1009-1015.
127. Engstrom RE Jr, Goldenberg DT, Parnell JR, et al. Clear lens extraction with intraocular lens implantation during retinal detachment repair in patients with Acquired Immune Deficiency Syndrome (AIDS) [correction of autoimmune deficiency syndrome] and cytomegalovirus retinitis. Ophthalmology. 2002;109:666-673.
128. Schaller UC, MacDonald JC, Mueller AJ, et al. Removal of silicone oil with vision improvement after rhegmatogenous retinal detachment following CMV retinitis in patients with AIDS. Retina. 1999;19:495-498.
129. Canzano JC, Morse LS, Wendel RT. Surgical repair of cytomegalovirus- related retinal detachment without silicone oil in patients with AIDS. Retina. 1999;19:274-280.
130. Cassoux N, Bodaghi B, Lautier-Frau M, et al. Current status of retinal detachment in AIDS patients. J Fr Ophtalmol. 2000;23:1031-1034.
131. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137:435-478.
132. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443-1445.
133. Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis. 2001;183:1285-1289.
134. Zegans M, Marsh B, Walton RC. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Int Ophthalmol Clin. 2000;40:127-135.